Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Immunogen (IMGN)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: IMGN
Coverage
Top Authors
Cramer
1 new
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
Sep 11
•
Justin M. Hall
•
ALTH
,
ARIA
,
ARQL
•
23 Comments
'When There's Blood in the Streets', Buy Biotech Stocks
Oct 10, 2008
•
Ohad Hammer
•
ALNY
,
ALTH
,
AMGN
•
13 Comments
Cancer Stocks Hammered Once Again
Jun 26, 2007
•
Alan Brochstein
•
ABPI
,
AFFY
,
AGEN
•
7 Comments
20 'Bathwater Babies' and 3 'Dogs with Fleas' for the Week
Mar 2
•
J Clinton Hill
•
AFAM
,
ALK
,
ALTH
•
5 Comments
Immunogen and Seattle Genetics: Verging on an Inflection Point
May 27, 2008
•
Ohad Hammer
•
CRGN
,
DNA
,
IMGN
•
4 Comments
Immunogen’s Bright Future
Oct 9, 2007
•
Ohad Hammer
•
IMGN
•
4 Comments
Immunogen's Bright Future (Part II)
Oct 18, 2007
•
Ohad Hammer
•
IMGN
•
4 Comments
Why is Wall Street Ignoring ImmunoGen?
May 16, 2008
•
Beta Delta
•
IMGN
•
4 Comments
Immunogen's Wild Swings Due to Lack of Information at ASCO
Jul 14, 2008
•
Ohad Hammer
•
DNA
,
IMGN
,
SGEN
•
3 Comments
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Sep 20
•
Justin M. Hall
•
AGN
,
ALTH
,
ARIA
•
3 Comments
The "Naked" Truth About Antibodies For Cancer Therapy
Jul 5, 2007
•
Ohad Hammer
•
AMGN
,
DNA
,
IMCL
•
3 Comments
Genentech's Trastuzumab-Dm1 Shows Great Promise in Treating Breast Cancer
Jan 6
•
Beta Delta
•
DNA
,
IMGN
•
3 Comments
Bright Prospects for Micromet (Part 2)
Apr 24
•
Ohad Hammer
•
IMGN
,
MEDX
,
MITI
•
3 Comments
Cancer Stocks on the Go: Winners and Losers
May 29, 2007
•
Alan Brochstein
•
ABPI
,
ACEL
,
AFFY
•
3 Comments
Cancer Stocks Plunge Following ASCO Meeting
Jun 11, 2007
•
Alan Brochstein
•
ABPI
,
ACEL
,
AFFY
•
3 Comments
Curagen: Positive Results at ASCO 2009
Jul 7
•
Ohad Hammer
•
CLDX
,
CRGN
,
IMGN
•
2 Comments
Genentech’s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans
Aug 6, 2008
•
Ohad Hammer
•
DNA
,
IMGN
,
SGEN
•
2 Comments
Top Biotech Picks for ASCO 2009 (Part II)
May 27
•
Ohad Hammer
•
ARQL
,
CRGN
,
EXEL
•
2 Comments
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO
Jun 1
•
Mike Havrilla
•
ALTH
,
AZN
,
BVTI.PK
•
2 Comments
ASCO: Whose Presentations Look the Most Promising?
May 27, 2008
•
Dan Rosenblum
•
ARIA
,
CELG
,
IMCL
•
2 Comments
Cancer Stocks Slide Again
Jun 18, 2007
•
Alan Brochstein
•
ABPI
,
ACEL
,
AFFY
•
1 Comment
PowerHouse Week for Economic Calendar
Oct 29, 2007
•
Michael Shaffer
•
AAP
,
ABN
,
ADP
•
1 Comment
ImmunoGen at ASH 2007 (Part I)
Dec 30, 2007
•
Ohad Hammer
•
IMGN
•
1 Comment
Micromet: Biting Cancer
Feb 6, 2008
•
Ohad Hammer
•
IMGN
,
MITI
,
SGEN
•
1 Comment
Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches
May 18
•
Mike Havrilla
•
ALTH
,
AMGN
,
CRGN
•
1 Comment
The Future of ImmunoGen - Care of Genentech
Mar 17, 2008
•
Beta Delta
•
DNA
,
IMGN
•
1 Comment
Cancer Stocks Soar With Annual ASCO Meeting
Jun 4, 2007
•
Alan Brochstein
•
ABPI
,
ACEL
,
AFFY
•
1 Comment